Scholarlink

Aim <p>To evaluate the acceptability of MyCheck for asymptomatic sexually transmissible infections (STIs) testing.</p> Background <p>Regular testing for STIs in at-risk populations is recommended by Australian guidelines as many STIs are asymptomatic. Consequently, MyCheck was developed to enhance access by combining a telehealth consultation with direct referral to pathology, avoiding the need for in-person clinic visits. MyCheck was piloted at Sydney Sexual Health Centre (SSHC)—the largest publicly funded urban sexual health clinic in New South Wales—between June 2021 and February 2022.</p> Methods <p>MyCheck integrated telehealth assessment with electronic referrals to over 500 pathology centres and automated result entry into the clinic’s patient management system. Staff initiated MyCheck testing offers to asymptomatic clients without complex care needs. Evaluation was based on clinic data and client surveys.</p> Results <p> Staff offered MyCheck to 9.8% (718/7340) of eligible clients. Of those, approximately two-thirds (472/718) accepted the offer and two-thirds (315/472) attended a pathology collection center. Females were more likely to accept the offer of MyCheck compared to males (RR: 1.2, 95% CI: 1.1-1.4). Clients who arrived in Australia more than 10 years ago were more likely (RR: 1.2, 95% CI: 1.0-1.4) to accept MyCheck testing compared to those who recently arrived. Clients who were on HIV-Pre exposure prophylaxis (PrEP) were less likely to accept MyCheck testing (RR: 0.8, 95% CI: 0.6-1.0) compared with clients not on PrEP. Relative to other existing asymptomatic testing services, the majority of MyCheck survey respondents rated MyCheck highly on location of pathology collection centers, quick test turnaround, and appointment availability. However, only ~50% of clients rated support for questions about safe and stigma free environment, and familiarity highly. Of all the visits to a pathology collection centre, 17.8% (56/315), resulted in a positive STI diagnosis (40 chlamydia, 26 gonorrhoea, 3 Mycoplasma genitalium, and one case of early latent syphilis), with all diagnoses linked to treatment.</p> Conclusions <p>MyCheck was well-received by clients and effective as an STI screening and management testing pathway. Offer of MyCheck to clients was a limiting factor.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of a novel comprehensive sexual health e-testing pathway to inform state-wide roll out in new South wales, Australia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月25日

查看全文
  • Prital Patel,
  • Nigel Carrington,
  • Heng Lu,
  • Lise Lafferty,
  • Nathan Ryder,
  • Carolyn Slattery,
  • Rochelle Avasalu,
  • Rebecca Houghton,
  • Aurelie Kenisberg,
  • Anna McNulty

摘要

Aim

To evaluate the acceptability of MyCheck for asymptomatic sexually transmissible infections (STIs) testing.

Background

Regular testing for STIs in at-risk populations is recommended by Australian guidelines as many STIs are asymptomatic. Consequently, MyCheck was developed to enhance access by combining a telehealth consultation with direct referral to pathology, avoiding the need for in-person clinic visits. MyCheck was piloted at Sydney Sexual Health Centre (SSHC)—the largest publicly funded urban sexual health clinic in New South Wales—between June 2021 and February 2022.

Methods

MyCheck integrated telehealth assessment with electronic referrals to over 500 pathology centres and automated result entry into the clinic’s patient management system. Staff initiated MyCheck testing offers to asymptomatic clients without complex care needs. Evaluation was based on clinic data and client surveys.

Results

Staff offered MyCheck to 9.8% (718/7340) of eligible clients. Of those, approximately two-thirds (472/718) accepted the offer and two-thirds (315/472) attended a pathology collection center. Females were more likely to accept the offer of MyCheck compared to males (RR: 1.2, 95% CI: 1.1-1.4). Clients who arrived in Australia more than 10 years ago were more likely (RR: 1.2, 95% CI: 1.0-1.4) to accept MyCheck testing compared to those who recently arrived. Clients who were on HIV-Pre exposure prophylaxis (PrEP) were less likely to accept MyCheck testing (RR: 0.8, 95% CI: 0.6-1.0) compared with clients not on PrEP. Relative to other existing asymptomatic testing services, the majority of MyCheck survey respondents rated MyCheck highly on location of pathology collection centers, quick test turnaround, and appointment availability. However, only ~50% of clients rated support for questions about safe and stigma free environment, and familiarity highly. Of all the visits to a pathology collection centre, 17.8% (56/315), resulted in a positive STI diagnosis (40 chlamydia, 26 gonorrhoea, 3 Mycoplasma genitalium, and one case of early latent syphilis), with all diagnoses linked to treatment.

Conclusions

MyCheck was well-received by clients and effective as an STI screening and management testing pathway. Offer of MyCheck to clients was a limiting factor.